Genetics of Opisthorchis viverrini -related cholangiocarcinoma

Current Opinion in Gastroenterology

Volumn 31, Issue 3, 2015, Pages 258-263

  Jusakul, Apinya ^a,b   Kongpetch, Sarinya ^a,b,c,d   Teh, Bin Tean ^a,b,e  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c KHON KAEN UNIVERSITY   (Thailand)

^d KHON KAEN UNIVERSITY   (Thailand)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

cholangiocarcinoma; liver fluke; Opisthorchis viverrini; TP53

Indexed keywords

MICRORNA; DNA BINDING PROTEIN; IMMUNOGLOBULIN RECEPTOR;

BILE DUCT CARCINOMA; CANCER GENETICS; CARCINOGENESIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; COPY NUMBER VARIATION; DNA DAMAGE; DNA METHYLATION; EPIGENETICS; EXOME; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; NONHUMAN; OPISTHORCHIASIS; REVIEW; XENOBIOTIC METABOLISM; ANIMAL; BILE DUCT TUMOR; DNA SEQUENCE; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; GENETICS; ISOLATION AND PURIFICATION; OPISTHORCHIS; PARASITOLOGY; PATHOLOGY; TRANSCRIPTION INITIATION;

ANIMALS; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; DNA-BINDING PROTEINS; EXOME; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VARIATION; HUMANS; OPISTHORCHIS; RECEPTORS, IMMUNOLOGIC; SEQUENCE ANALYSIS, DNA; TRANSCRIPTIONAL ACTIVATION;

EID: 84928577913     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000162     Document Type: Review

References (44)

1. Sripa B, Brindley PJ,Mulvenna J, et al. The tumorigenic liver fluke Opisthorchis viverrini-multiple pathways to cancer. Trends Parasitol 2012; 28:395-407.
2. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 2013; 145:1215-1229.
3. Sithithaworn P, Yongvanit P, Duenngai K, et al. Roles of liver fluke infection as risk factor for cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2014; 21:301-308.
4. IARC. Infection with liver flukes (Opisthorchis viverrini, Opisthorchis felineus and Clonorchis sinensis). IARC Monogr Eval Carcinog Risks Hum 1994; 61:121-175.
5. Pinlaor S, Hiraku Y, Ma N, et al. Mechanism of NO-mediated oxidative and nitrative DNA damage in hamsters infected with Opisthorchis viverrini: A model of inflammation-mediated carcinogenesis. Nitric Oxide 2004; 11:175-183.
6. Thanan R, Pairojkul C, Pinlaor S, et al. Inflammation-related DNA damage and expression of CD133 and Oct3/4 in cholangiocarcinoma patients with poor prognosis. Free Radic Biol Med 2013; 65:1464-1472.
7. Dechakhamphu S, Pinlaor S, Sitthithaworn P, et al. Accumulation of miscoding etheno-DNA adducts and highly expressed DNA repair during liver flukeinduced cholangiocarcinogenesis in hamsters. Mutat Res 2010; 691:9-16.
8. Sia D, Tovar V, Moeini A, et al. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene 2013; 32:4861-4870.
9. Muenphon K, Limpaiboon T, Jearanaikoon P, et al. Amplification of chromosome 21q22.3 harboring trefoil factor family genes in liver fluke related cholangiocarcinoma is associated with poor prognosis. World J Gastroenterol 2006; 12:4143-4148.
10. Limpaiboon T, Tapdara S, Jearanaikoon P, et al. Prognostic significance of microsatellite alterations at 1p36 in cholangiocarcinoma. World J Gastroenterol 2006; 12:4377-4382.
11. Thanasai J, Limpaiboon T, Jearanaikoon P, et al. Amplification of D22S283 as a favorable prognostic indicator in liver fluke related cholangiocarcinoma. World J Gastroenterol 2006; 12:4338-4344.
12. Dachrut S, Banthaisong S, Sripa M, et al. DNA copy-number loss on 1p36.1 harboring RUNX3 with promoter hypermethylation and associated loss of RUNX3 expression in liver fluke-associated intrahepatic cholangiocarcinoma. Asian Pac J Cancer Prev 2009; 10:575-582.
13. Miller G, Socci ND, Dhall D, et al. Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract. J Exp Clin Cancer Res 2009; 28:62.
14. McKay SC, Unger K, Pericleous S, et al. Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma. HPB (Oxford) 2011; 13:309-319.
15. Andersen JB, Thorgeirsson SS. Genetic profiling of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol 2012; 28:266-272.
16. Limpaiboon T, Khaenam P, Chinnasri P, et al. Promoter hypermethylation is a major event of hMLH1 gene inactivation in liver fluke related cholangiocarcinoma. Cancer Lett 2005; 217:213-219.
17. Sriraksa R, Zeller C, El-Bahrawy MA, et al. CpG-island methylation study of liver fluke-related cholangiocarcinoma. Br J Cancer 2011; 104:1313-1318.
18. Cui Y, Ying Y, van Hasselt A, et al. OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS One 2008; 3:e2990.
19. Sriraksa R, Zeller C, Dai W, et al. Aberrant DNA methylation at genes associated with a stem cell like phenotype in cholangiocarcinoma tumors. Cancer Prev Res (Phila) 2013; 6:1348-1355.
20. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: Approaches and considerations. Nat Rev Genet 2012; 13:358-369.
21. Plieskatt JL, Rinaldi G, Feng Y, et al. Distinct miRNA signatures associate with subtypes of cholangiocarcinoma from infection with the tumourigenic liver fluke Opisthorchis viverrini. J Hepatol 2014; 61:850-858.
22. Chen L, Yan HX, Yang W, et al. The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J Hepatol 2009; 50:358-369.
23. Selaru FM, Olaru AV, Kan T, et al. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 2009; 49:1595-1601.
24. Chusorn P, Namwat N, Loilome W, et al. Overexpression of microRNA-21 regulating PDCD4 during tumorigenesis of liver fluke-associated cholangiocarcinoma contributes to tumor growth and metastasis. Tumour Biol 2013; 34:1579-1588.
25. Ong CK, Subimerb C, Pairojkul C, et al. Exome sequencing of liver flukeassociated cholangiocarcinoma. Nat Genet 2012; 44:690-693.
26. Chan-On W, Nairismagi ML, Ong CK, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and noninfection-related bile duct cancers. Nat Genet 2013; 45:1474-1478.
27. Farazi PA, Zeisberg M, Glickman J, et al. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res 2006; 66:6622-6627.
28. Rashid A, Ueki T, Gao YT, et al. K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: A population-based study in China. Clin Cancer Res 2002; 8:3156-3163.
29. Robertson S, Hyder O, Dodson R, et al. The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome. Hum Pathol 2013; 44:2768-2773.
30. Jiao Y, Pawlik TM, Anders RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 2013; 45:1470-1473.
31. Wu J, Matthaei H, Maitra A, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 2011; 3:92ra66.
32. Tannapfel A, Benicke M, Katalinic A, et al. Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 2000; 47:721-727.
33. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003; 425:577-584.
34. Chuang SC, Lee KT, Tsai KB, et al. Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers. World J Surg 2004; 28:995-1000.
35. Jiang X, Hao HX, Growney JD, et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci USA 2013; 110:12649-12654.
36. Jiang X, Yu Y, Yang HW, et al. The imprinted gene PEG3 inhibits Wnt signaling and regulates glioma growth. J Biol Chem 2010; 285:8472-8480.
37. Shinada K, Tsukiyama T, Sho T, et al. RNF43 interacts with NEDL1 and regulates p53-mediated transcription. Biochem Biophys Res Commun 2011; 404:143-147.
38. Deng Y, Wu X. Peg3/Pw1 promotes p53-mediated apoptosis by inducing Bax translocation from cytosol to mitochondria. Proc Natl Acad Sci USA 2000; 97:12050-12055.
39. Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012; 491:399-405.
40. Chen C, Liu Y, Rappaport AR, et al. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell 2014; 25:652-665.
41. Nie Z, Yan Z, Chen EH, et al. Novel SWI/SNF chromatin-remodeling complexes contain a mixed-lineage leukemia chromosomal translocation partner. Mol Cell Biol 2003; 23:2942-2952.
42. Wang P, Dong Q, Zhang C, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 2013; 32:3091-3100.
43. Jinawath N, Chamgramol Y, Furukawa Y, et al. Comparison of gene expression profiles between. Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma. Hepatology 2006; 44:1025-1038.
44. Ito T, Sakurai-Yageta M,Goto A, et al. Genomic and transcriptional alterations of cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2014; 21:380-387.